VSee Health Stock Surges 125% on FedRAMP High Authorization
VSee Health shares skyrocketed 125% in premarket trading following its FedRAMP High authorization from the U.S. Department of Health and Human Services. The green light enables federal agencies to deploy VSee's telehealth platform for secure healthcare applications, removing procurement barriers and unlocking potential contracts with entities like the Department of Defense and CDC.
The company recently demonstrated its crisis-response capabilities by rapidly deploying a telemedicine system for HHS after a cyberattack disrupted a U.S. Virgin Islands hospital. Its platform processed over 250 backlogged radiology studies within days—a proof point for its government-ready infrastructure.
While bullish analysts tout a $5 price target, skeptics flag financial instability concerns. The news follows VSee's $10 million teleradiology contract win and $5 million debt elimination from its SPAC merger, strengthening its position for upcoming government opportunities.